The mission of the Institute for Drug Education and Research is to serve as a vehicle to educate Ph.D. and Pharm.D./Ph.D. students and postdoctoral associates specifically in the areas of drug delivery and pre-clinical/clinical pharmacokinetics; perform translational research in the development of drug delivery systems for anticancer agents and drugs for other indications; and provide consultation services to the pharmaceutical industry, hospitals and research institutions.
The primary research focus of IDER is in nanotechnology for cancer therapy, using approaches of nanoparticles, microemulsions, liposomes and other platforms, through injectable, implantable, oral and transdermal deliveries.
The scopes of research embrace pre-formulation, formulation, in vitro assessments (stability, drug release and transdermal permeation, cytotoxicity in cancer cell lines, etc.) and in vivo pharmacokinetic/ pharmacodynamic (PK/PD) evaluations in animal models, using conventional monitoring techniques and/or microdialysis.
The IDER offers expertise in pharmaceutical formulations to effectively deliver the active agents for pre-clinical and clinical evaluations, as well as PK/PD evaluation services for translational research.
Diana S-L. Chow, Ph.D., FNAI
Xinli Liu, Ph.D.
Romi Ghose, Ph.D.
Bin Guo, Ph.D.
Ke-He Ruan, M.D., Ph.D.
Adjunct Faculty/External Collaborators
Dong Liang, Ph.D., Texas Southern University
Lei Wu, Ph.D., AbbVie Pharmaceuticals
For more information, please contact:
Diana Chow, Ph.D., FNAI
University of Houston College of Pharmacy
4349 Martin Luther King Boulevard, Room 3044
Houston, TX 77204-5037
832-842-8308 or 832-842-8302